View Pages
SpaceX Drops on AI Spending; Eli Lilly Rises; DaVita Slides on US Dialysis Revenue
SpaceX tumbles after massive AI-driven capex and modest AI revenue; Eli Lilly raises 2026 sales outlook on strong weight-loss drug performance; DaVita slips as US dialysis revenue misses estimates.
Editorial companion
What stands out
DaVita slid after reporting weaker-than-expected United States (US) dialysis revenue and a guidance midpoint that came in below Wall Street's expectations, a reminder that hospital and clinic operators still move on cash flow details, not headlines. The miss matters because DaVita otherwise shows mid-single-digit revenue growth and double-digit net-income growth, so the market is punishing a near-term top-line hiccup rather than discarding the entire story. For investors, this episode underscores how sensitive dialysis chains are to volumes, payer mixes and the cadence of reimbursements even when guidance is reaffirmed.
Bullish Gator Snapshot
Current ratings and signals
DaVita (DVA)
Neutral
DVA rates Neutral overall. The fundamental read is bearish: the company passes 6 of 9 quality tests on the Piotroski F-Score; balance sheet is flagged Distress (Altman Z = 1.63); revenue is growing about 5.6% per year; net income is growing about 12.9% per year. The technical picture is bullish: price is 4.9% above the 200-day moving average; 1.7% above the 50-day; the 50/200 relationship is in a Golden cross. Sentiment is neutral (composite 52/100), based on 8 news articles from recent coverage.